Cobourn Steven P. 4

What Happened

• Steven P. Cobourn, Chief Financial Officer of NextCure, was granted a derivative award (an option) covering 14,670 shares on January 30, 2026. The filing reports the acquisition at $0.00 (derivative award), with a reported value of $0 on the Form 4 (reporting convention for option grants).

Key Details

• Transaction date: 2026-01-30 (reported on Form 4 filed 2026-02-03).
• Award amount: options covering 14,670 shares; reported acquisition price $0.00 (derivative).
• Vesting: one-fourth vests on January 30, 2027; the remaining three-fourths vest in 36 monthly installments beginning February 28, 2027 (per footnote F1).
• Shares owned after transaction: not specified in the provided excerpt of the Form 4.
• Filing timeliness: Form 4 filed on Feb 3, 2026 — within the usual 2-business-day reporting window for Form 4 (timely).

Context

• This is a grant of derivative securities (an option award) as part of executive compensation, not an open-market purchase or sale. There was no immediate sale or exercise reported; vesting is time-based. Such awards are common for retention and incentive pay and do not by themselves indicate a buy/sell signal.